Dasatinib Plus Chemo Achieves Long-Term Remission in Ph+ Acute Leukemia

Share this content:
Combination of chemotherapy with dasatinib is effective in achieving long-term remission for in Ph+ acute lymphoblastic leukemia.
Combination of chemotherapy with dasatinib is effective in achieving long-term remission for in Ph+ acute lymphoblastic leukemia.

A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a new study published online ahead of print in the journal Cancer has shown.1

For the study, researchers enrolled 72 patients with Ph+ ALL. All participants received dasatinib with 8 cycles of alternating hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, and high-dose cytarabine with methotrexate.

Those who achieved complete remission continued maintenance dasatinib plus vincristine and prednisone for 2 years, followed by dasatinib indefinitely. If patients were eligible to undergo allogeneic stem cell transplantation, they received it during their first complete response.

Results showed 96% achieved a complete response. Of those, 83% achieved cytogenetic complete response after 1 cycle and 93% achieved a major molecular response at a median of 4 weeks.

Researchers found that 94% of patients were negative for minimal residual disease at a median of 3 weeks. The median disease-free survival and overall survival were 31 months and 47 months, respectively.

RELATED: Dasatinib-induced Pulmonary Hypertension in Patients With Leukemia

At a median follow-up of 67 months, 46% were alive and 43% were in complete response.

In regard to safety, the most common dasatinib-associated grade 3 and 4 adverse events included bleeding, pleural/pericardial effusions, and elevated transaminases.

Reference

  1. Ravandi F, O'Brien SM, Cortes JE, et al; Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [published online ahead of print August 26, 2015]. Cancer. doi: 10.1002/cncr.29646.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs